With the acquisition of Phase 2 ready assets from Cresence AS, Bioasis becomes a clinical stage company with a multi-asset pipeline focused on rare and orphan drugs.
Moreover, Bioasis recently announced partnerships with Janssen Biotech, a Johnson & Johnson company, and Korea-based Neuramedy Co. to ensure their proprietary xB3 technology is used as broadly as possible.